RE: Treatment only Vaccines won’t work31 Mar 2020 00:15
How much rise tomorrow? 10%?
Synairgen’s treatment is a formulation of interferon beta delivered by a nebuliser designed to protect the lungs of patients with COPD from exacerbations such as coronavirus.
It is especially important with people with pre-existing conditions, says Marsden, as by that stage the lungs are compromised too much to cope with any additional complications.
In a note, analysts at 'house' broker finnCap introduced a 120p target price on the firm, saying the company's risk/reward profile was "skewed significantly to the upside" and that a successful outcome from the pilot phase of SNG001 will have "substantial commercial value".
"It is clear from the equity market’s positive reaction to [coronavirus] clinical events...that the market potential is enormous. With c.1 in 6 coronavirus-infected patients becoming severely ill, the potential number of treatments rises into the 100ks, creating a potential US$1bn+ product opportunity", finnCap said.